Rickell Gordon
Family · Rochester, NYNPI 1093132052
Payments from drug & device makers
Across 163 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novo Nordisk$1K
- AbbVie$804
- AstraZeneca$470
- Bayer$349
- Exact Sciences$274
- plus $822 from 10 others
What the payments were for
- Food & beverage$4,837100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 27 | $1,073 |
| Novo Nordisk | 43 | $1,046 |
| AbbVie | 22 | $804 |
| AstraZeneca | 9 | $470 |
| Bayer | 12 | $349 |
| Exact Sciences | 14 | $274 |
| Lilly USA, LLC | 12 | $239 |
| Pfizer | 9 | $169 |
| Sanofi-aventis U.S. LLC | 3 | $154 |
| GSK | 4 | $100 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 1 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,837 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $37,152 |
| RybelsusSemaglutide | 32 | $30,690 |
| EliquisApixaban | 31 | $19,364 |
| JanuviaSitagliptin Phosphate | 21 | $12,348 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $7,123 |
| Levothyroxine Sodium | 273 | $2,599 |
| Atorvastatin Calcium | 191 | $2,468 |
| Rosuvastatin Calcium | 155 | $2,399 |
| SynthroidLevothyroxine Sodium | 37 | $2,202 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $2,181 |
| Ezetimibe | 43 | $1,898 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,583 |
| Metoprolol Succinate | 57 | $1,235 |
| Gabapentin | 64 | $886 |
| Potassium Chloride | 23 | $876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,046 | $67,84367 claims |
| PfizerEliquis | $169 | $19,36431 claims |
| AstraZenecaBreztri Aerosphere | $470 | $7,12314 claims |
| AbbVieSynthroid | $804 | $2,20237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.
Other family in Rochester
- Stephanie BartlettRochester$63K
- Orlando HarrisRochester$30K
- Laron NelsonRochester$28K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.